Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency

Jonathon W. Senefeld^{1#}, PhD, Stephen A. Klassen^{1#}, PhD, Shane K. Ford^{1#}, BS, Chad C. Wiggins¹, PhD, Bruce C. Bostrom², MD, Michael A. Thompson, MD, PhD³, Sarah E. Baker¹, PhD, Wayne T. Nicholson¹, MD, Patrick W. Johnson⁴, BS, Rickey E. Carter⁴, PhD, Jeffrey P. Henderson⁵, MD, PhD, William R. Hartman⁶, MD, Liise-anne Pirofski⁷, MD, R. Scott Wright⁸, MD, DeLisa Fairweather⁹, PhD, Katelyn A. Bruno⁹, PhD, Nigel S. Paneth^{10†}, MD, Arturo Casadevall^{11†}, MD, PhD and Michael J. Joyner^{1†}*, MD

1 | Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota

2 | Pediatric Oncology & Hematology, Children's Hospital of Minnesota, Minneapolis, Minnesota

3 | Aurora Cancer Care, Advocate Aurora Health, Milwaukee, Wisconsin

4 | Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida

5 | Department of Medicine and Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri

6 | Department of Anesthesiology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin

7 | Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York

8 | Department of Cardiovascular Medicine and Director Human Research Protection Program, Mayo Clinic, Rochester, Minnesota

9 | Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida

10 | Department of Epidemiology and Biostatistics and Department of Pediatrics and Human Development, Michigan State University, East Lansing, Michigan

11 | Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

0 | Abstract

In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency.

1 | Introduction

Convalescent plasma represents a passive antibody therapy that has been used to prevent or treat infectious diseases for more than a century.^{1,2} In the context of the novel coronavirus disease 2019 (COVID-19) pandemic, convalescent plasma has received full or conditional regulatory authorization in the United States for therapeutic use in adults and children hospitalized with suspected or laboratory confirmed SARS-CoV-2 positive COVID-19.^{3–5} Although early signals for efficacy and optimal use of convalescent plasma have emerged,^{6–10} additional large randomized controlled trials are needed to garner clinical consensus regarding the therapeutic effectiveness of convalescent plasma.

Inasmuch as convalescent plasma confers antiviral properties for the recipient, evidence of therapeutic effectiveness may be confounded by endogenous anti-SARS-CoV-2 antibody responses, particularly when convalescent plasma transfusion occurs late in the disease course.¹¹ Hence, evaluation of the clinical responses to convalescent plasma transfusion in immunosuppressed patients who cannot generate innate immune responses may provide an optimal opportunity to assess the effect of convalescent plasma *per se.*¹² Thus, herein we summarize the literature detailing the clinical experiences of patients with primary and secondary immunosuppression who were transfused with COVID-19 convalescent plasma. We hypothesize that patients with immunodeficiency syndromes, or patients with diseases associated with blunted endogenous antibody responses to COVID-19, may provide evidence of improved clinical status when given plasma containing anti-SARS-CoV-2 antibodies, with improvements over and above expectation in light of their underlying clinical conditions and the severity of COVID-19.

This review highlights 40 reports including 104 COVID-19 patients with primary immunosuppression due to Agammaglobulinemia (X-linked or autosomal) or Common Variable Immunodeficiency, and secondary immunodeficiencies related to hematological malignancies and solid organ transplants who were transfused with convalescent plasma. We also highlight additional cases of patients with COVID-19, including but not limited to patients with other forms of immunosuppression, transfused with convalescent plasma. We provide a summary overview of patient characteristics, COVID-19 therapies used, including convalescent plasma, and clinical symptomology (table).

Search strategy and selection criteria

References for this Review were identified through searches of PubMed for articles published from Jan 1, 2020 to Nov 1, 2020, using the Medical Subject Headings terms "COVID-19", "convalescent plasma", "convalescent serum", "immunosuppression", "cancer", "transplant", "agammaglobulinemia", "malignancy", and any relevant entry terms and supplementary concepts (**figure**). Relevant articles and data were also identified through searches in Google Scholar, medR_xiv, and other websites. Articles resulting from these searches and relevant references cited in those articles were reviewed. Articles published in English were identified and included. All procedures accessed public information and did not require ethical review as determined by the Mayo Clinic Institutional Review Board in accordance with the Code of Federal Regulations, 45 CFR 46.102, and the Declaration of Helsinki.

2 | Primary Immunodeficiency

2.1 | Patients with Agammaglobulinemia

This narrative includes one patient with Autosomal Agammaglobulinemia and six patients with X-linked Agammaglobulinemia (XLA), six of whom were reported in peer-reviewed articles and one patient who was identified in a media report.^{13–16} Patients with Agammaglobulinemia do not produce endogenous antibodies and require regular intravenous infusions (monthly) or subcutaneous injections (bi-weekly) of immunoglobulins to avoid serial infections from various common pathogens.¹⁷ However, immunoglobulin replacement therapy cannot protect patients against pathogens for which antibodies are uncommon or absent in the immunoglobulin donor pool, such as the SARS-CoV-2 virus.¹⁷ The clinical narratives describing patients with Agammaglobulinemias all demonstrate a prolonged course of disease and absent antibody response to COVID-19. However, all patients with Agammaglobulinemia demonstrated clinical improvement and symptom resolution following convalescent plasma transfusion, with three patients improving rapidly and demonstrating SARS-CoV-2 serum antibodies after transfusion. In addition to immunoglobulin therapy, some patients also received the experimental COVID-19 therapies remdesivir and hydroxychloroquine.

2.2 | Patients with Common Variable Immunodeficiency

We identified four patients with Common Variable Immunodeficiency transfused with convalescent plasma for COVID-19 therapy.¹⁶ Common Variable Immunodeficiency represents a heterogeneous collection of immunodeficiencies commonly characterized by intrinsic B-cell defects and suppressed antibody production.¹⁸ Patients with Common Variable Immunodeficiency often present with inflammatory and autoimmune disorders, which are suspected to elevate these patients risk for progression to severe COVID-19.^{16,18} The four patients described here were all antibody deficient and diagnosed with severe or life-threatening COVID-19. Notably, three of these patients survived following convalescent plasma transfusion, including two patients whose clinical symptomatology required mechanical ventilation or extracorporeal membrane oxygenation.

3 | Secondary Immunodeficiency

3.1 | Patients with Hematological Malignancies

We identified 54 patients with hematological malignancies transfused with convalescent plasma in 18 peer-reviewed reports.^{19,20,28,29,29-36,21-24,24-27} The largest cohort of patients with hematological malignancies was a group of 17 patients with B-cell depletion whose immunodeficiency was secondary to therapies for various types of lymphoma or leukemia.¹⁹ These patients experienced protracted severe COVID-19 symptoms and absent endogenous SARS-CoV-2 antibody responses due to cancer-directed therapies that suppress B-cell proliferation, such as rituximab. Within 48 hours of convalescent plasma transfusion the majority of patients demonstrated improved clinical status and viral clearance. Similarly, in a separate cohort of 14 patients with hematological malignancies, most patients exhibited improvements in clinical symptomatology, including reduced oxygen requirements,²⁰ after treatment with convalescent plasma. Other case-reports are of lymphoma (n = 11), leukemia (n = 5), multiple myeloma (n = 3), and myelodysplastic syndrome (n = 1) and include one four year old pediatric patient with leukemia who received two convalescent plasma doses over two days.²⁸ A majority of patients with hematological malignancies recovered following convalescent plasma transfusion, with many demonstrating rapid clinical improvements shortly after transfusion. Notably, a patient with protracted COVID-19, evidenced by three separate COVID-19-related hospitalisations over a 100+ day period, and with lymphoma-associated B-cell immunodeficiency demonstrated rapid reductions in fever, oxygen requirements, and lung infiltrates (via chest computed tomography) forthwith after two separate convalescent plasma transfusions separated by ~90 days.²²

3.2 | Solid Organ Transplant Patients

Among nine peer-reviewed articles and two media reports we identified a total of 29 COVID-19 patients transfused with convalescent plasma whom were receiving immunosuppressive therapies for previous solid organ transplants.^{37–47} In a cohort of 13 transplant recipients transfused with convalescent plasma concomitant to hydroxychloroquine, steroids and anticoagulants therapies for COVID-19, eight patients demonstrated improved oxygen requirements and were promptly discharged ³⁷. In the other nine reports, a majority of the 17 patients with COVID-19 demonstrated improved clinical symptomatology following convalescent plasma transfusion. Improvement was even seen in a liver transplant patient discharged home after a convalescent plasma transfusion that occurred during a seventeen day medically-induced coma due to COVID-19 complications.⁴⁴

4 | Conclusion

These data provide evidence and encouraging anecdotal statements (**panel**) supporting the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency, and are consistent with the historical evidence demonstrating that passive antibody therapies for infectious diseases are especially effective when given early in the course of disease prior to an endogenous antibody response.^{2,48,49} In contrast to ongoing studies of convalescent plasma efficacy in clinical trials where the majority of patients are not immunosuppressed and thus mount their own protective antibody responses,^{6,11,50} convalescent plasma use in these immunosuppressed patients represents a situation where exogenous antibody is provided in the setting of an immune deficit.¹⁷ This is particularly true in the case for patients with Agammaglobulinemia, who represent in effect a natural 'immunological knockout' providing the opportunity to evaluate the value of adding specific antibody to a host unable to make antibody to SARS-CoV-2.

The results for patients with Agammaglobulinemia are striking for the beneficial effects of convalescent plasma, and even though the reports lack a control group, the rapid time course of clinical improvement following administration of specific antibody in a situation where no endogenous antibody was present is impressive. Convalescent plasma was also found to be safe and efficacious in COVID-19 patients with common variable immunodeficiency, myasthenia gravis, and Sjögren's syndrome, in addition to COVID-19 patients with heart rhythm abnormalities and gravida.^{51–57} Hence, from the viewpoint of establishing the efficacy of convalescent plasma administration in COVID-19 therapy, the experience with this patient set provides the important criterion that addition of specific antibody to a host with no antibodies resulted in a favorable therapeutic effect.

Contributors

MJJ is the guarantor. SAK, JWS, SKF, AC and MJJ conceptualised the paper, extracted the data and established the writing consortium. All authors contributed to the reviewing and editing of the report and approved the final version.

Declaration of interests We declare no competing interests.

Acknowledgements

We thank the members of the National COVID-19 Convalescent Plasma Project (http://ccpp19.org) for their support and collation of key scientific papers.

Funding/Support

This study was supported in part by National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 (to MJJ), grant F32HL154320 (to JWS), and grant RO1 HL059842 (to AC); Natural Sciences and Engineering Research Council of Canada (NSERC) PDF-532926-2019 (to SAK); National Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356, R21 AI152318 and R21 AI154927 (to DF), and grant R01 AI152078 9 (to AC); and National Institute on Aging (NIA) U54AG044170 (to SEB).

References

- 1 Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. *J Clin Invest* 2020; **130**: 1545–8.
- 2 Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med* 2006; **145**: 599–609.
- Bloch EM, Shoham S, Casadevall A, *et al.* Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest* 2020.
- 4 US Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. 2020. https://www.fda.gov/vaccines-blood-biologics/investigational-newdrug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19convalescent-plasma.
- 5 US Food and Drug Administration. Clinical Memorandum for the Emergency Use Authorization of COVID-19 Convalescent Plasma. 2020 https://www.fda.gov/media/141480/download.
- 6 Li L, Zhang W, Hu Y, *et al.* Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA* 2020.
- 7 Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical Efficacy of Convalescent Plasma for Treatment of COVID-19 Infections: Results of a Multicenter Clinical Study. Transfus Apher Sci 2020; : 102875.
- 8 Salazar E, Christensen PA, Graviss EA, *et al.* Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality. *medRxiv* 2020.
- 9 Joyner MJ, Senefeld JW, Klassen SA, *et al.* Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. *MedRxiv* 2020.
- 10 Joyner MJ, Bruno K, Klassen SA, *et al.* Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. *Mayo Clin Proc* 2020; **95**.
- 11 Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *bmj* 2020; **371**.
- 12 Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. *Front Immunol* 2019; **10**: 33.
- 13 Jin H, Reed JC, Liu STH, *et al.* Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. *J Allergy Clin Immunol Pract* 2020.
- 14 Mira E, Yarce OA, Ortega C, *et al.* Rapid recovery of a SARS-CoV-2–infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. *J Allergy Clin Immunol Pract* 2020; **8**: 2793–5.
- 15 Flaherty C. Man leaves hospital after three month battle with Covid-19. Impartial Report. 2020. https://www.impartialreporter.com/news/18599490.man-leaves-hospital-three-month-battle-covid-19/ (accessed Oct 25, 2020).
- 16 Meyts I, Bucciol G, Quinti I, *et al.* Coronavirus Disease 2019 in patients with inborn errors of immunity: an international study. *J Allergy Clin Immunol* 2020.
- 17 Mazhar M, Waseem M. Agammaglobulinemia. In: StatPearls [Internet]. StatPearls Publishing, 2020.
- 18 Abbott JK, Gelfand EW. Common variable immunodeficiency: diagnosis, management, and treatment. *Immunol Allergy Clin* 2015; **35**: 637–58.
- 19 Hueso T, Pouderoux C, Péré H, *et al.* Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease. *Blood* 2020.
- 20 Tremblay D, Seah C, Schneider T, *et al.* Convalescent Plasma for the Treatment of Severe COVID□19 Infection in Cancer Patients. *Cancer Med* 2020.
- 21 Hatzl S, Eisner F, Schilcher G, et al. Response to "COVID-19 in persons with haematological

cancers". Leukemia 2020; 34: 2265-70.

- 22 Baang JH, Smith C, Mirabelli C, *et al.* Prolonged SARS-CoV-2 replication in an immunocompromised patient. *medRxiv* 2020.
- 23 Lancman G, Mascarenhas J, Bar-Natan M. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. *J Hematol Oncol* 2020; **13**: 1–3.
- 24 Moore JL, Ganapathiraju P V, Kurtz CP, Wainscoat B. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. *Am J Case Rep* 2020; **21**: e927812.
- 25 Çınar OE, Sayınalp B, Karakulak EA, *et al.* Covalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated Tuberculosis. *Transfus Apher Sci* 2020; : 102821.
- 26 Karataş A, İnkaya AÇ, Demiroğlu H, *et al.* Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. *Transfus Apher Sci* 2020; : 102871.
- 27 Luetkens T, Metcalf R, Planelles V, *et al.* Successful transfer of anti–SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. *Blood Adv* 2020; **4**: 4864–8.
- 28 Shankar R, Radhakrishnan N, Dua S, *et al.* Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia. *Transfus Apher Sci* 2020; : 102956.
- 29 Wright Z, Bersabe A, Eden R, Cap A. Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma. *Clin Lymphoma Myeloma Leuk* 2020.
- 30 Clark E, Guilpain P, Filip IL, *et al.* Convalescent plasma for persisting Covid □ 19 following therapeutic lymphocyte depletion: a report of rapid recovery. *Br J Haematol* 2020; **190**: e154–6.
- 31 Niu A, McDougal A, Ning B, *et al.* COVID-19 in allogeneic stem cell transplant: high falsenegative probability and role of CRISPR and convalescent plasma. *Bone Marrow Transplant* 2020; : 1–3.
- 32 Pal P, Ibrahim M, Niu A, *et al.* Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients. *Transfus Med* 2020.
- 33 Abid MB, Chhabra S, Buchan B, *et al.* Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. *Hematol Oncol Stem Cell Ther* 2020.
- 34 Malsy J, Veletzky L, Heide J, *et al.* Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. *Clin Infect Dis* 2020.
- 35 Wang B, Van Oekelen O, Mouhieddine T, *et al.* A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. *medRxiv* 2020.
- 36 Zhang LL, Liu Y, Guo YG, *et al.* Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis. *Turkish J Haematol Off J Turkish Soc Haematol* 2020.
- 37 Rahman F, Liu STH, Taimur S, *et al.* Treatment with convalescent plasma in solid organ transplant recipients with COVID □ 19: Experience at large transplant center in New York City. *Clin Transplant* 2020; : e14089.
- 38 Fung M, Nambiar A, Pandey S, *et al.* Treatment of Immunocompromised COVID 19 patients with Convalescent Plasma. *Transpl Infect Dis* 2020.
- 39 Trimarchi H, Gianserra R, Lampo M, Monkowski M, Lodolo J. Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. 2020.
- 40 Naeem S, Gohh R, Bayliss G, *et al.* Successful recovery from COVID □ 19 in three kidney transplant recipients who received convalescent plasma therapy. *Transpl Infect Dis* 2020; : e13451.
- Lima B, Gibson GT, Vullaganti S, *et al.* COVID □ 19 in recent heart transplant recipients: Clinicopathologic features and early outcomes. *Transpl Infect Dis* 2020; : e13382.
- 42 Jiang J, Miao Y, Zhao Y, *et al.* Convalescent plasma therapy: Helpful treatment of COVID □ 19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications. *Clin Transplant* 2020; **34**: e14025.

- 43 WDRB Media and Fox 59. Plasma donation helps save Indiana man diagnosed with COVID-19. 2020. https://www.wdrb.com/news/coronavirus/plasma-donation-helps-save-indiana-mandiagnosed-with-covid-19/article_540bc9b2-ac1d-11ea-958d-abf6e203c27a.html.
- 44 NHS Blood and Transplant. One of the first COVID-19 convalescent plasma recipients supports donor appeal. Give Blood. 2020. https://www.blood.co.uk/news-and-campaigns/news-and-statements/one-of-the-first-covid-19-convalescent-plasma-recipients-supports-donor-appeal/.
- 45 Bartosch J. Lung transplant patient with COVID-19 recovers following plasma clinical trial. Univ. Chicago Med. 2020. https://www.uchicagomedicine.org/forefront/coronavirus-disease-covid-19/lung-transplant-patient-with-covid-19-recovers-following-plasma-clinical-trial.
- 46 Choudhury A, Reddy GS, Venishetty S, *et al.* COVID-19 in Liver Transplant Recipients-A Series with Successful Recovery. *J Clin Transl Hepatol* 2020; **8**: 1–7.
- 47 Christensen J, Kumar D, Moinuddin I, *et al.* Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients. In: Transplantation proceedings. Elsevier, 2020.
- 48 Cheng Y, Wong R, Soo YOY, *et al.* Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis* 2005; **24**: 44–6.
- 49 Hung IFN, To KKW, Lee C-K, *et al.* Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis* 2011; **52**: 447–56.
- 50 Gharbharan A, Jordans CCE, GeurtsvanKessel C, *et al.* Convalescent Plasma for COVID-19. A randomized clinical trial. *medRxiv* 2020.
- 51 Diorio C, Anderson EM, McNerney KO, *et al.* Convalescent plasma for pediatric patients with SARS CoV 2 associated acute respiratory distress syndrome. *Pediatr Blood Cancer* 2020; **67**: e28693.
- 52 Aksoy E, Oztutgan T. COVID-19 presentation in association with myasthenia gravis: a case report and review of the literature. *Case Rep Infect Dis* 2020; **2020**.
- 53 Hartman W, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest. *medRxiv* 2020.
- 54 Jafari R, Jonaidi-Jafari N, Dehghanpoor F, Saburi A. Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report. *World J Radiol* 2020; **12**: 137.
- 55 Pelayo J, Pugliese G, Salacup G, *et al.* Severe COVID-19 in Third Trimester Pregnancy: Multidisciplinary Approach. *Case Reports Crit Care* 2020; **2020**.
- 56 Rodriguez Z, Shane AL, Verkerke H, *et al.* COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease. *Blood Adv* 2020; **4**: 4278.
- 57 Ye M, Fu D, Ren Y, *et al.* Treatment with convalescent plasma for COVID □ 19 patients in Wuhan, China. *J Med Virol* 2020.

Condition	No. Patients	WHO Disease Severity Scale*	Illness onset to Treatment (days)*	Mortality (n, %)	Rapid Improvement in Supplemental Oxygen (≤5 days) (n, %)*	Discharge (days)*
Primary Immunosuppresion						
Agammaglobulinemia	7	3.4 (2 - 5)	26.3 (16 - 44)	0, 0%	2, 50%	4.3 (1-7)
Common Variable Immune Deficiency	4	2.8 (2 - 5)		1, 25%		
Secondary Immunosuppression						
Hematological Malignancies	54	3.2 (2 - 5)	23.8 (2 - 90)	7,13.0%	22, 61.1%	17.1 (2 - 50)
Solid Organ Transplants	29	3.9 (2 - 5)	10.6 (2 - 31)	4, 13.8%	14, 56.0%	14.0 (2 - 58)
Other ^a						
	10	4.0 (3 - 5)	14.3 (6 - 39)	1, 10.0%	4, 40.0%	18.1 (1.5 - 60)

Data are presented as mean (range) or count (n), mean (%). *Data were not reported for all patients, please see Supplement 1 for additional information. ^aOther includes pediatric patients, patients with congenital heart disease, gravida patients, and patients with Sjögren's syndrome

Table: Summary of each patient's hospital course and disposition after transfusion of COVID-19 convalescent plasma.

Panel: Anecdotal statements supporting the efficacy of convalescent plasma

- In the present case, the rapid clinical improvement followed by viral clearance after administration of hyperimmune plasma argue that passively transferred antibodies played a key role in COVID-19 recovery.²³
- One day later [after convalescent plasma transfusion], the patient was afebrile for the first time in 3 weeks and had improved energy.¹³
- On day 122 (of illness), due to worsening symptoms, the patient was given convalescent plasma. He defervesced within 24 hours and was discharged nine days later.³¹
- ...she was transferred to the intensive care unit for intubation. In the meantime...the patient received convalescent therapy instead and did not undergo intubation following the immediate improvement after plasma therapy infusion.⁵²
- Based on the lack of clinical improvement...we transfused 1 unit of convalescent plasma...Importantly, the patient did not receive any other treatment potentially having an effect on the course of COVID-19...After transfusion of the convalescent plasma, the patient showed a dramatic clinical improvement, became asymptomatic, and was discharged home only 2 days later.³⁶
- The patient was discharged after 2 weeks [convalescent plasma transfusion] with a dramatic response to therapy. Both newborns had no COVID-19 symptoms and negative PCR results.⁵⁴
- 36 hours after [convalescent plasma] transfusion, the patient was discharged from the hospital reporting that he felt improved.⁵³
- COVID-19 antibody testing showed complete lack of COVID-19 antibodies...She received 2 units of convalescent plasma...with rapid improvement in oxygen requirements. She was weaned off high-flow nasal cannula within 48 h and within a few days was discharged home in stable condition.³²
- Intravenous convalescent plasma...was administered...Her health condition quickly improved, allowing [withdrawal of oxygen supplementation]...²³
- Within a day of receiving her first transfusion of convalescent plasma, she reported improvement in shortness of breath and cough, had fever resolution, and decreasing oxygen requirements.²⁴
- She received COVID convalescent plasma...She showed remarkable improvement [the next day]...with reduction of respiratory rate...and oxygen requirements.²¹
- ...the patient received a transfusion of convalescent plasma...one day later her [arterial oxygen saturation] increased to 98%...clinical symptoms and pathological criteria improved rapidly within 3 days.²⁹
- Within hours after receiving the convalescent plasma... [The patient's] fever started going down. Days later, his breathing and kidney function improved.⁴⁵
- [The patient]...received a transfusion of convalescent plasma...He is recovering at home after spending two and a half weeks in a coma fighting for his life...⁴⁴
- ...received 217 mL of convalescent plasma...24 hours later, his heart rate had improved to 60-70 bpm with less frequent premature atrial contractions and premature ventricular contractions and he was breathing comfortably on room air...36 hours after transfusion the patient was discharged from the hospital...⁵³
- Stagnancy in the patient's evolution, as represented by the lack of response to any of the treatments dispensed....we administered on day 23 COVID-19 convalescent plasma...after 24 hours of infusion, fever ceased without subsequent reappearance and with progressive improvement of asthenia.¹⁴




Figure: Flowchart of the study selection.

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency

Most Recent Update: November 8, 2020

Study	Patient #	Condition	Age (years)	Sex	WHO Disease Severity Scale
Primary Immunosuppre	sion				
Agammaglobulinemia					
Jin et al.	1	X-Linked Agammaglobulinemia	10	Male	4
	2	X-Linked Agammaglobulinemia	24	Male	3
	3	X-Linked Agammaglobulinemia	40	Male	3
Meyts et al.	1	(Pt. #11) Autosomal Agammaglobulinemia	35-44	Male	5
	2	(Pt. #18) X-Linked Agammaglobulinemia	3-12	Male	3-4
Flaherty	1	X-Linked Agammaglobulinemia	32	Male	
Mira et al.	1	X-Linked Agammaglobulinemia	39	Male	2
Common Variable Imm	ine Deficiency				
Meyts et al.	1	(Pt. #2) Common Variable Immune Deficiency	35-44	Female	2
	2	(Pt. #13) Common Variable Immune Deficiency	13-18	Male	5
	3	(Pt. #46) Common Variable Immune Deficiency	25-34	Male	2
	4	(Pt. #69) Common Variable Immune Deficiency	65-74	Female	2
econdary Immunosupp	ression				
Hematological Malign	ancies				
Hueso et al.	1-17	Diffuse large B-Cell lymphoma, 4 Mantle cell lymphoma, 3 Follicular lymphoma, 3 Chronic lymphocytic leukemia, 3 Marginal zone lymphoma, 1 Waldentröm Macroglubulinemia, 1 Multiple sclerosis, 1 Common variable immune deficiency, 1	(35-77)	Male, 12 Female, 5	2-5
Tremblay et al.	1-14	Non-Hodgkin lymphoma, 5 Multiple myeloma, 4 Acute lymphoblastic leukemia, 2 Hodgkin lymphoma, 1 Myelofibrosis, 1 Chronic lymphocytic leukemia, 1	(31-88)	Male, 8 Female, 6	3-5
Pal et al.	1	(Pt. #1) Diffuse large B-cell lymphoma/central nervous system lymphoma	70	Female	3
	2	(Pt. #2) Acute Myeloid Lymphoma	30	Male	2
	3	(Pt. #4) Acute Lymphoblastic Leukemia	53	Female	3
	4	(Pt. #11) Acute Lymphoblastic Leukemia	64	Male	3
	5	(Pt. #12) Follicular Lymphoma	68	Female	4
	6	(Pt. #13) Acute Myeloid Lymphoma	24	Male	2
Abid et al.	1	(Pt. #1) Myelodysplastic Syndrome	76	Male	5

	2	(Pt. #2) Multiple Myeloma	88	Male	3
Hatzl et al.	1	Diffuse large B-Cell lymphoma	52	Male	5
	2	Follicular lymphoma	55	Male	5
Baang et al.	1	Refractory mantle cell lymphoma	60	Male	3
Cinar et al.	1	Myelodysplastic syndrome	55	Male	3
Clark et al.	1	Orbital and Meningeal Marginal Zone Lymphoma Mixed Cellularity Classical Hodgkin Lymphoma, Peripheral T-cell lymphoma, Autologous Stem-Cell	76	Female	4
Karatas et al.	1	Transplant	61	Male	3
Lancman et al.	1	B-Cell acute lymphoblastic leukemia	55	Female	4
Luetkens et al.	1	Immunoglobulin G k multiple myeloma	72	Female	3
Malsy et al.	1	Follicular lymphoma	53	Female	2
Moore et al.	1	Non-Hodgkin lymphoma	63	Female	2
Niu et al.	1	B-cell acute lymphoblastic leukemia, Allogenic stem-cell transplant	53	Female	3
Shankar et al.	1	B-Lineage Acute Lymphoblastic Leukemia	4	Female	3
Wang et al.	1	Multiple Myeloma			
Wright et al.	1	Follicular Lymphoma	54	Male	3
Zhang et al.	1	Myeloid Leukemia	46	Female	2
Organ Transplants					
Rahman et al.	1-13		51 (20-75)	Male, 8 Female, 5	3-5
	1	Kidney Transplant			3
	2	Kidney Transplant			3
	3	Kidney Transplant			4
	4	Kidney Transplant			4
	5	Liver & Kidney Transplant			4
	6	Kidney Transplant			3
	7	Kidney Transplant			4
	8	Heart Transplant			3
	9	Liver Transplant			3
	10	Liver Transplant			3
	11	Liver Transplant			3
	12	Liver Transplant			4
	13	Kidney & Pancreas Transplant			3
Fung et al.	1	Kidney Transplant	44	Male	5
	2	Kidney Transplant	44	Male	4
	3	Bilateral Lung Transplant & Sjögrens Syndrome	65	Female	3
	4	Chronic myelogenous leukemia	62	Male	4
Naeem et al.	1	Kidney Transplant	65	Female	2
	2	Kidney Transplant	35	Female	5
	3	Kidney Transplant	36	Male	5
Lima et al.	1	(Pt #4) Heart Transplant	62	Male	5
	2	(Pt #5) Heart Transplant	68	Male	5
Bartosch	1	Lung Transplant	30	Male	

1	Liver Transplant	52	Male	4
1	(Pt. #3) Kidney transplant	64	Female	5
1	Kidney Transplant	70	Female	4
1	Liver Transplant	49	Male	5
1	Kidney Transplant	24	Male	3
1	Kidney Transplant	64	Female	5
1	(CD4) Pediatric Patient	18	Female	5
2	(CD15) Pediatric Patient	15	Female	4
3	(CD17) Pediatric Patient	17	Female	4
4	(CD25) Pediatric Patient	14	Female	5
1	Myasthenia Gravis	46	Female	4
1	Asthma, Chronic Obstructive Pulmonary Disease, Sinus Bradycardia	62	Male	3
1	Gravida (36 weeks)	26	Female	3
1	Gravida (36 weeks)	35	Female	4
1	Congenital Heart Disease, Trisomy 21	9 weeks	Female	5
1	Sjögrens Syndrome	63	Female	3
	1 1 1 1 1 1 2 3 4 1 1 1 1 1 1 1 1 1 1 1 1 1	1(Pt. #3) Kidney transplant1Kidney Transplant1Liver Transplant1Kidney Transplant1Kidney Transplant1(CD4) Pediatric Patient2(CD15) Pediatric Patient3(CD17) Pediatric Patient4(CD25) Pediatric Patient1Myasthenia Gravis1Asthma, Chronic Obstructive Pulmonary Disease, Sinus Bradycardia1Gravida (36 weeks)1Gravida (36 weeks)1Congenital Heart Disease, Trisony 21	1(Pt. #3) Kidney transplant641Kidney Transplant701Liver Transplant491Kidney Transplant241Kidney Transplant641(CD4) Pediatric Patient182(CD15) Pediatric Patient153(CD17) Pediatric Patient174(CD25) Pediatric Patient141Myasthenia Gravis461Asthma, Chronic Obstructive Pulmonary Disease, Sinus Bradycardia621Gravida (36 weeks)351Congenital Heart Disease, Trisomy 219 weeks	1(Pt. #3) Kidney transplant64Female1Kidney Transplant70Female1Liver Transplant49Male1Kidney Transplant24Male1Kidney Transplant64Female1(CD4) Pediatric Patient18Female2(CD15) Pediatric Patient15Female3(CD17) Pediatric Patient17Female4(CD25) Pediatric Patient14Female1(CD25) Pediatric Patient14Female1Myasthenia Gravis46Female1Asthma, Chronic Obstructive Pulmonary Disease, Sinus Bradycardia62Male1Gravida (36 weeks)26Female1Gravida (36 weeks)35Female1Congenital Heart Disease, Trisomy 219 weeksFemale

Supplementary Table 1: Summary of patient's characteristics prior to transfusion of COVID-19 convalescent plasma.

Study	Patient #	Illness onset to Treatment (days)	Mortality, n, %	Improvement in Supplemental Oxygen (≤5 days), n, %	Treatment to Discharge (days)
Primary Immunosuppresion					
Agammaglobulinemia					
Jin et al.	1	22	0, 0%	0, 0%	6
	2	16	0, 0%	0, 0%	3
	3	44	0, 0%	1, 100%	1
Meyts et al.	1		0, 0%		
	2		0, 0%		
Flaherty	1				
Mira et al.	1	23	0, 0%	1, 100%	7
Common Variable Immune De	ficiency				
Meyts et al.	1		1,100%		
	2		0, 0%		
	3		0, 0%		
	4		0, 0%		
Secondary Immunosuppression	1				
Hematological Malignancies					
Hueso et al.	1-17	56 (7-83)	1, 5.9%		7 [2-14]
Tremblay et al.	1-14	3 [2-7]	5, 35.7%	4, 28.6%	
Pal et al.	1	4	0, 0%	1, 100%	4
	2	5	0,0%	0, 0%	5
	3	5	0,0%	1, 100%	12
	4	10	0,0%	1, 100%	12
	5	18	0, 0%	1, 100%	24
	6	5	0, 0%	0, 0%	41
Abid et al.	1	10	1,100%	0, 0%	
	2	5	0, 0%	1, 100%	7
Hatzl et al.	1	14	0, 0%	1, 100%	46
	2	19	0, 0%	1, 100%	38
Baang et al.	1	31	0, 0%	1, 100%	8
Cinar et al.	1	5	0,0%	1, 100%	10
Clark et al.	1	50	0,0%	1, 100%	19
Karatas et al.	1	40	0, 0%	1, 100%	38
Lancman et al.	1	81	0, 0%	1, 100%	~5
Luetkens et al.	1	3	0, 0%	1, 100%	2
Malsy et al.	1	~90	0, 0%	0, 0%	~50
Moore et al.	1	88	0, 0%	1, 100%	2
Niu et al.	1	4 & 13	0,0%	1, 100%	10
Shankar et al.	1	8 & 9	0, 0%	1, 100%	10
Wang et al.	1				RH
Wright et al.	1	24	0, 0%	1, 100%	7
Zhang et al.	1	5	0, 0%	1, 100%	9
Organ Transplants			5, 570	-, -0070	
Rahman et al.	1-13	10.2	3, 23.1%	8,61.5%	≤7 days, 6
	1	7	0, 0%	1, 100%	
	2	5	0, 0%	1, 100%	
	2	6	0, 0%	1, 100%	
	4	15	1, 100%	0, 0%	
	4 5	9	1, 100% 1, 100%	0,0%	
	6 7	11	0,0%	0,0%	
	7 8	31 12	1, 100% 0, 0%	0, 0% 1, 100%	

	9	7	0,0%	1, 100%	
	10	11	0, 0%	1, 100%	
	11	4	0, 0%	1, 100%	
	12	7	0, 0%	0,0%	
	13	8	0, 0%	1,100%	
Fung et al.	1	27	0, 0%	0,0%	46
	2	4	0, 0%	1, 100%	11
	3	8	0, 0%	1,100%	2
	4	3	0, 0%	0,0%	58
Naeem et al.	1	7	0, 0%	1,100%	2
	2	3	0, 0%	0,0%	21
	3	2	0, 0%	1, 100%	13
Lima et al.	1		0, 0%		RH
	2		0, 0%		RH
Bartosch	1		0, 0%	1,100%	6
Choudhury et al.	1	8	0, 0%	1, 100%	6
Christensen et al.	1		1,100%	0,0%	
Jiang et al. NHS Blood and	1	26	0, 0%	0, 0%	26
Transplant	1	24	0, 0%		
Trimarchi et al. WDRB Media and Fox	1	9	0, 0%	1, 100%	5
59	1		0, 0%		
Other					
Diorio et al.	1	14	1,100%	0,0%	
	2	7	0, 0%	0,0%	RH
	3	11	0, 0%	0,0%	RH
	4	11	0, 0%	0,0%	17
Aksoy et al.	1	6	0, 0%	1, 100%	16
Hartman et al.	1	7	0, 0%	1, 100%	1.5
Jafari et al.	1	6	0, 0%	0,0%	8
Pelayo et al.	1		0, 0%	0,0%	
Rodriguez et al.	1	28-32	0, 0%	1, 100%	~60
Ye et al.	1	39	0, 0%	1,100%	6

Supplementary Table 2: Summary of patient's hospital course and disposition after transfusion of COVID-19 convalescent plasma.

		Concomitar				1
Study	Patient #	IVIG	Steroids	remdesivir	(hydoxy)chloroquine	antibiotics
Primary Immunosuppresion						
Agammaglobulinemia						
Jin et al.	1	Y		Y		
	2	Y				Y
	3					Y
Meyts et al.	1	Y			Y	Y
	2			Y		Y
Flaherty	1			Y		1
Mira et al.	1	Y		1	Y	Y
		1			1	1
Common Variable Immune Deficien		V	V		V	v
Meyts et al.	1	Y	Y		Y	Y
	2		Y	Y		Y
	3	Y	Y		Y	Y
	4				Y	Y
econdary Immunosuppression						
Hematological Malignancies						
Hueso et al.	1-17		Y	Y	Y	Y
Tremblay et al.	1-14			Y	Y	
Pal et al.	1			Y		
	2			Y		
	3					
	4					
	5			Y		
	6			-		
Abid et al.	1			Y		
and than	1 2			1		
Hotel of al	2		Y		Y	Y
Hatzl et al.						
D (1	2		Y	V	Y	Y
Baang et al.	1			Y		
Cinar et al.	1					
Clark et al.	1		Y			
Karatas et al.	1				Y	Y
Lancman et al.	1		Y		Y	Y
Luetkens et al.	1		Y			
Malsy et al.	1			Y		
Moore et al.	1					
Niu et al.	1	Y				Y
Shankar et al.	1	Y	Y			Y
Wang et al.	1					
Wright et al.	1				Y	Y
Zhang et al.	1					Y
Drgan Transplants	·					
Rahman et al.	1-13		Y		Y	
	1					
	2					
	3					
	4					
	5					
	6					
	7					
	8					
	9					
	10					

			1		1	
	11	 				
	12	 				
	13	 				
Fung et al.	1	Y		Y	Y	
	2					
	3		Y			
	4					
Naeem et al.	1	Y				
	2	Y	Y		Y	
	3	Y	Y		Y	
Lima et al.	1	Y				
	2	Y				
Bartosch	1	 				
Choudhury et al.	1	Y	Y	Y	Y	
Christensen et al.	1			Y		
Jiang et al.	1	Y			Y	
NHS Blood and Transplant	1	 				
Trimarchi et al.	1	Y			Y	
WDRB Media and Fox 59	1	 				
Other						
Diorio et al.	1	Y		Y		
	2		Y			
	3	Y	Y			
	4	Y				
Aksoy et al.	1	Y		Y	Y	
Hartman et al.	1	Y				
Jafari et al.	1			Y	Y	
Pelayo et al.	1	Y	Y			
Rodriguez et al.	1		Y	Y		
Ye et al.	1				Y	

Supplementary Table 3: Summary of patient's concomitant COVID-19 therapeutics prior to transfusion of COVID-19 convalescent plasma.